Shots:

• Skyhawk to receive $80M up front- milestones- and royalties on sales. Celgene to get exclusive WW option to license IPR for the number of Skyhawk's candidates targeting multiple autoimmune disorder- oncology- and immuno-oncology targets. Post option exercising- Celgene will be responsible for further development and commercialization of products
• In 2018- the companies collaborated to discover and develop therapies utilizing Skyhawk’s STAR technology platform for the treatment of autoimmune disorders- oncology- and immuno-oncology diseases
• Skyhawk’s SkySTAR (Small molecule Therapeutics for Alternative splicing of RNA platform) allows identifying of druggable sites and unique chemical matter for correcting mRNA mis-splicing resulting in novel therapies

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance